Eli Lilly became the first publicly traded pharmaceutical company to exceed a $500 billion market capitalization.
Eli Lilly crossed the $500 billion valuation level in 2023 as investors responded to strong demand expectations for its diabetes and obesity medicines, especially Mounjaro and Zepbound. The company’s market value rose as clinical results and commercial forecasts increased confidence in these drug categories.
Founded in 1876 by Colonel Eli Lilly, the Indianapolis-based company has developed medicines across diabetes, oncology, neuroscience, immunology, and other fields. Its long history includes the commercial development of insulin products and several widely used prescription medicines.
The milestone is about a pharmaceutical company’s public-market value, not the sales of a single drug. Eli Lilly’s valuation also changes with share prices, patent expectations, clinical outcomes, regulatory decisions, and competition from other drugmakers.